Ng L, Yu W, Aung N, Leung P, Luk J, Wong D
Cancer Rep (Hoboken). 2024; 7(12):e70069.
PMID: 39617741
PMC: 11608892.
DOI: 10.1002/cnr2.70069.
Gray M, Sotomayor M
Acta Crystallogr F Struct Biol Commun. 2021; 77(Pt 3):85-94.
PMID: 33682793
PMC: 7938635.
DOI: 10.1107/S2053230X21002247.
Casal J, Bartolome R
Int J Mol Sci. 2019; 20(13).
PMID: 31324051
PMC: 6651558.
DOI: 10.3390/ijms20133373.
Khedr M, Messaoudi W, Jonnalagadda U, Abdelmotelb A, Glynne-Jones P, Hill M
Biomicrofluidics. 2019; 13(1):014112.
PMID: 30867882
PMC: 6404912.
DOI: 10.1063/1.5082603.
Shek F, Luo R, Lam B, Sung W, Lam T, Luk J
Cell Oncol (Dordr). 2017; 40(5):443-456.
PMID: 28631187
DOI: 10.1007/s13402-017-0332-x.
Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K, Ushiku T, Urabe M, Fukuyo M, Abe H, Ishikawa S
Oncotarget. 2016; 7(39):64168-64181.
PMID: 27580354
PMC: 5325433.
DOI: 10.18632/oncotarget.11638.
Cadherin 17 is a sensitive and specific marker for metanephric adenoma.
Yakirevich E, Magi-Galluzzi C, Grada Z, Lu S, Resnick M, Mangray S
Am J Surg Pathol. 2015; 39(4):479-86.
PMID: 25768256
PMC: 4360917.
DOI: 10.1097/PAS.0000000000000401.
Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.
Lin Z, Zhang C, Zhang M, Xu D, Fang Y, Zhou Z
PLoS One. 2014; 9(1):e85296.
PMID: 24465527
PMC: 3896370.
DOI: 10.1371/journal.pone.0085296.
Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.
Wang Y, Shek F, Wong K, Liu L, Zhang X, Yuan Y
PLoS One. 2013; 8(9):e72386.
PMID: 24039755
PMC: 3770615.
DOI: 10.1371/journal.pone.0072386.
Involvement of liver-intestine cadherin in cancer progression.
Takamura M, Yamagiwa S, Matsuda Y, Ichida T, Aoyagi Y
Med Mol Morphol. 2013; 46(1):1-7.
PMID: 23306661
DOI: 10.1007/s00795-012-0003-y.
Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis.
Mokrowiecka A, Zonnur S, Veits L, Musial J, Kordek R, Lochowski M
Dig Dis Sci. 2012; 58(3):699-705.
PMID: 23053896
PMC: 3616226.
DOI: 10.1007/s10620-012-2425-8.
Dickkopfs and Wnt/β-catenin signalling in liver cancer.
Fatima S, Lee N, Luk J
World J Clin Oncol. 2011; 2(8):311-25.
PMID: 21876852
PMC: 3163259.
DOI: 10.5306/wjco.v2.i8.311.
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.
Xu M, Chan S, Liu A, Wong K, Fan S, Chen J
Oncogene. 2010; 30(10):1229-40.
PMID: 21076472
PMC: 3330262.
DOI: 10.1038/onc.2010.504.
Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.
Weimann A, Rieger A, Zimmermann M, Gross M, Hoffmann P, Slevogt H
Virchows Arch. 2010; 457(5):537-45.
PMID: 20844891
DOI: 10.1007/s00428-010-0972-y.
Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.
Berasain C, Goni S, Castillo J, Latasa M, Prieto J, Avila M
World J Gastroenterol. 2010; 16(25):3091-102.
PMID: 20593494
PMC: 2896746.
DOI: 10.3748/wjg.v16.i25.3091.
Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer.
Liu Q, Zhang J, Liu M, Dong W
Cancer Sci. 2010; 101(8):1807-12.
PMID: 20500517
PMC: 11159871.
DOI: 10.1111/j.1349-7006.2010.01600.x.
Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA.
Zhang J, Liu Q, Dong W
Med Oncol. 2010; 28(2):494-501.
PMID: 20393816
DOI: 10.1007/s12032-010-9489-0.
A protein-based set of reference markers for liver tissues and hepatocellular carcinoma.
Sun S, Yi X, Poon R, Yeung C, Day P, Luk J
BMC Cancer. 2009; 9:309.
PMID: 19725976
PMC: 2742551.
DOI: 10.1186/1471-2407-9-309.
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.
Liu L, Lee N, Chan V, Xue W, Zender L, Zhang C
Hepatology. 2009; 50(5):1453-63.
PMID: 19676131
PMC: 3328302.
DOI: 10.1002/hep.23143.
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.
Xu M, Yao T, Lee N, Ng I, Chan Y, Zender L
Cancer. 2009; 115(19):4576-85.
PMID: 19551889
PMC: 2811690.
DOI: 10.1002/cncr.24495.